Hinge Health’s long-anticipated IPO is generating significant buzz as the first major digital health offering since Waystar’s debut in 2024, raising questions about whether the public markets will value Hinge at or near its prior $6.2 billion private valuation. While the company has shown impressive revenue growth to $390.4M in 2024 and improved margins, concerns remain about future growth beyond the saturated self-insured employer market and its ability to expand beyond musculoskeletal (MSK) care into adjacent areas like behavioral health or GI. As a leader in digital MSK, Hinge faces pressure to either build or buy capabilities in new clinical categories to meet employers’ growing demand for consolidated solutions.
Trending
- Where GI practices are struggling, succeeding (Becker’s GI & Endoscopy)
- Physician shortage and private equity: the ruin of U.S. health care (KevinMD)
- Why leading physicians will move to concierge medicine in 2026 with Greg Grant of Specialdocs (Physicians Practice)
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy (Nature)
- Stiffer colon could signal risk of early-onset colorectal cancer (Medical Xpress)
- Successful GI Sign-off Protocol Incorporates Primary Care Feedback (GI & Endoscopy News)
- Earlier and More Intensive Advanced Therapy Use Fails to Improve 10-Year Crohn’s Outcomes (Docwire News)
- CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1 (HIT Consultant)
